In a xenograft model, combination treatment with anti-PD-L1 and anti-CD73 antibodies significantly suppressed tumor growth, increased the number of tumor-infiltrating CD8+ T cells, and enhanced IFN-γ and TNF-α production by these T cells [212]. The gene discussed is CD8A; the disease is neoplasm.